$84.98
+1.5%Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Healthy operating margins demonstrate effective cost control and strong business fundamentals.
Moderate profitability with room for improvement. Monitor interest expenses and tax efficiency.
Moderate tax rate typical for most corporations. Represents standard tax burden on profits.
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
ZBH โข NYSE
| Zimmer Biomet Holdings, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
8.2B | 7.7B | 7.4B | 6.9B | 6.8B | 6.1B | 8B | 7.9B | 7.8B | 7.7B | 6B | 4.7B | 4.6B | 4.5B | 4.5B | 4.2B | 4.1B | 4.1B | 3.9B | 3.5B | |
GROSS PROFIT | ||||||||||||||||||||
(3.2B) | (2.2B) | (2.1B) | (2B) | (2B) | (1.8B) | (2.3B) | (2.3B) | (2.1B) | (2.4B) | (1.8B) | (1.2B) | (1.3B) | (1.1B) | (1.1B) | (1B) | (990.7M) | (997.3M) | (875.9M) | (780.1M) | |
5.1B | 5.5B | 5.3B | 4.9B | 4.9B | 4.3B | 5.7B | 5.7B | 5.7B | 5.3B | 4.2B | 3.4B | 3.3B | 3.3B | 3.3B | 3.2B | 3.1B | 3.1B | 3B | 2.7B | |
OPERATING INCOME | ||||||||||||||||||||
(3.7B) | (4.2B) | (4B) | (4.2B) | (4B) | (4.2B) | (4.6B) | (5.6B) | (4.9B) | (4.5B) | (3.7B) | (2.4B) | (2B) | (2.3B) | (2.3B) | (2.3B) | (2.1B) | (2B) | (1.9B) | (1.6B) | |
(3.3B) | (2.9B) | (2.8B) | (2.8B) | (2.8B) | (2.7B) | (3.3B) | (3.4B) | (3.1B) | (2.9B) | (2.7B) | (2B) | (1.8B) | (1.9B) | (1.9B) | (1.8B) | (1.8B) | (1.8B) | (1.5B) | (1.4B) | |
(458.5M) | (437.4M) | (458.7M) | (406M) | (435.8M) | (322.8M) | (449.3M) | (391.7M) | (369.9M) | (365.6M) | (268.8M) | (191.9M) | (204.2M) | (225.6M) | (238.4M) | (218.5M) | (205.7M) | (192.3M) | (209.6M) | (188.3M) | |
1.4B | 1.3B | 1.3B | 696.3M | 860.3M | 83.1M | 1.1B | 33.8M | 799.3M | 821.1M | 467.3M | 1B | 1B | 1B | 1B | 916.7M | 1B | 1.1B | 1.1B | 1.2B | |
PRE-TAX INCOME | ||||||||||||||||||||
(292.8M) | (218M) | (201.2M) | (164.8M) | (208.4M) | (212.1M) | (226.9M) | (289.3M) | (325.3M) | (355M) | (286.6M) | (63.1M) | (70.1M) | (72.9M) | (55.3M) | (60.2M) | (20.6M) | (0.0) | (0.0) | (0.0) | |
-292.8M | -218M | -201.2M | -164.8M | -208.4M | -212.1M | -226.9M | -289.3M | -325.3M | -355M | -277.2M | -51.2M | -54.5M | -57.3M | -45.2M | -56.5M | -20.6M | 31.8M | 0.0 | 0.0 | |
(0.0) | (834.5M) | (735.1M) | (1.1B) | (727.4M) | (1.2B) | (799M) | (1.9B) | (1.4B) | (1.2B) | (800.6M) | (223.1M) | (6M) | (161.2M) | (203.8M) | (306.8M) | (116.2M) | (68.5M) | (194.7M) | (6.1M) | |
-531.4M | -249.1M | -210.4M | -292.8M | -361.3M | -188.3M | -231.7M | -304.9M | -334.7M | -421.5M | -314.1M | -97.9M | -87.5M | -57.3M | -45.2M | -56.5M | -20.6M | 31.8M | 4M | 3.8M | |
830.8M | 1B | 1.1B | 403.5M | 499M | -105.2M | 905.8M | -271.1M | 464.6M | 399.6M | 153.2M | 939.4M | 981.1M | 990.1M | 978.9M | 860.2M | 998.2M | 1.1B | 1.1B | 1.2B | |
NET INCOME | ||||||||||||||||||||
(125.7M) | (131.4M) | (42.2M) | (112.3M) | (53.5M) | -96M | -225.7M | (108.2M) | -1.3B | (95M) | (7M) | (220.2M) | (221.9M) | (237.2M) | (218.9M) | (263.3M) | (280.8M) | (272.3M) | (357.9M) | (334M) | |
705.2M | 903.8M | 1B | 231.4M | 401.6M | -138.9M | 1.1B | -379.2M | 1.8B | 305.9M | 147M | 720.3M | 761M | 755M | 760.8M | 596.9M | 717.4M | 848.6M | 773.2M | 834.5M |
ZBH - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 27, 2026 | May 22, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 01, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 28, 2026 | April 22, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 28, 2026 | April 28, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 01, 2026 | May 22, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 20, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 10, 2026 | February 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 08, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 05, 2025 | November 05, 2025 | 2025 |
Continue your ZBH research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.